| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:Vandetanib (trifluoroacetate)
CAS:338992-53-3
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
| Products Intro: |
Product Name:Vandetanib trifluoroacetate
CAS:338992-53-3
Purity:>98% HPLC Package:10mg;100mg;1g Remarks:Reagent Grade
|
|
| | ZD 6474 trifluoroacetate Basic information |
| Product Name: | ZD 6474 trifluoroacetate | | Synonyms: | Vandetanib (trifluoroacetate);ZactiMa trifluoroacetate;ZD 6474 trifluoroacetate;ZD6474 trifluoroacetate;ZD-6474 trifluoroacetate;ZACTIMA TRIFLUOROACETATE; ZD6474 TRIFLUOROACETATE; ZD-6474 TRIFLUOROACETATE; ZD 6474 TRIFLUOROACETATE;ZD6474 TRIFLUOROACETATE;ZD-6474 TRIFLUOROACETATE;ZD 6474 TRIFLUOROACETATE | | CAS: | 338992-53-3 | | MF: | C24H25BrF4N4O4 | | MW: | 589.39 | | EINECS: | | | Product Categories: | | | Mol File: | 338992-53-3.mol |  |
| | ZD 6474 trifluoroacetate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | ZD 6474 trifluoroacetate Usage And Synthesis |
| Description | Vandetanib trifluoroacetate is a potent inhibitor of VEGFR2 with IC50 of 40 nM. | | in vitro | In Vitro:Vandetanib inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC50 of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC50 of 2.7 μM (A549) to 13.5 μM (Calu-6)[1]. Odanacatib is a weak inhibitor of antigen presentation, measured in a mouse B cell line (IC50=1.5±0.4 μM), compared to the Cat S inhibitor LHVS (IC50=0.001 μM) in the same assay. Odanacatib also shows weak inhibition of the processing of the MHC II invariant chain protein Iip10 in mouse splenocytes compared to LHVS (minimum inhibitory concentration 1-10 μM versus 0.01 μM, respectively)[2]. Vandetanib suppresses phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibits cell proliferation[4]. | | in vivo | In Vivo:Vandetanib (15 mg/kg, p.o.) has a superior anti-tumor effect than gefitinib in the H1650 xenograft model, and suppresses tumor growth with IC50 of 3.5±1.2 μM[3]. In tumor-bearing mice, vandetanib (50 or 75 mg/kg) suppresses phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduces tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and upregulates VEGF, TGF-α, and EGF in tumor tissues[4]. | | References | References:[1]. Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55.
[2]. Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84(3):260-7.
[3]. Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417-23.
[4]. Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012 Jul 15;18(14):3924-33. |
| | ZD 6474 trifluoroacetate Preparation Products And Raw materials |
|